ContactDictionary

Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  abiraterone acetate
Find trials that include:  Any drugs shown
Results 1-21 of 21 for your search:
Start Over
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
Status: Active
Phase: Phase III
Type: Treatment
Age: Any age
Trial IDs: CR100797, NCI-2013-00686, 2011-005243-28, 212082PCR3010, NCT01517802
Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: D081DC00007, NCI-2017-00284, NCT02987543
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CO39303, NCI-2017-00917, NCT03072238
A Study of Rucaparib Verses Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CO-338-063, NCI-2017-01110, NCT02975934
Abiraterone Acetate in Treating Patients with Hormone-Resistant Prostate Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 11-0709, NCI-2012-00116, NCT01543776
Abiraterone Acetate, Radiation Therapy, and Hormone Therapy in Treating Patients with Unfavorable-Risk Localized Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 20 to 80
Trial IDs: Pro00044071, NCI-2013-01803, NCT01717053
Testosterone Therapy Followed by Enzalutamide or Abiraterone Acetate in Treating Patients with Prostate Cancer That Is Progressing on Combined Androgen Therapies
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J1416, NCI-2014-01366, CIR00006889, CIR00011018, NA_00093344, NCT02090114
Abiraterone Acetate with or without Cabazitaxel in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-046, NCI-2014-01894, c12-108, NCT02218606
Abiraterone Acetate, Prednisone, and Apalutamide with or without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0386, NCI-2016-00670, NCT02703623
Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients with Hormone-Resistant Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 19 and over
Trial IDs: UCDCC#260, NCI-2016-00779, NCT02807805
A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men with Localized Prostate Cancer Pre-prostatectomy
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9628, NCI-2016-01027, NCT02849990
Apalutamide, Abiraterone Acetate, Prednisone, Leuprolide Acetate, and Stereotactic, Ultra-hypofractionated Radiation Therapy in Treating Patients with Very High Risk Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-334, NCI-2016-01304, NCT02772588
Apalutamide with or without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients with High-Risk Prostate Cancer Undergoing Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 081603, NCI-2016-01496, Pro20160000563, NCT02949284
Abiraterone Acetate and Apalutamide before and after Surgery in Treating Patients with Intermediate-High Risk Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-223, NCI-2016-01764, NCT02903368
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 9785-CL-0123, NCI-2016-02000, 2016-001694-32, NCT02960022
Abiraterone Acetate, Olaparib, and Prednisone in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer with DNA Repair Defects
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NU 16U05, NCI-2016-01834, STU00203960, NCT03012321
Rapid Cycle Combination Therapy in Treating Patients with Metastatic Castrate-Resistant Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 16-1593, NCI-2017-00934, NCT02903160
Apalutamide, Abiraterone Acetate, and Prednisone in Treating Patients with Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: Pro00075097, NCI-2017-01132, NCT03098836
Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer
Status: Not yet active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 204697, NCI-2017-01126, NCT03150056
Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: MCC-17981, NCI-2015-00648, 15.01.0005, NCT02415621
Cognitive Assessment and MRI Program in Identifying Cognitive Effects of Androgen Receptor Directed Therapies in Patients with Advanced Prostate Cancer
Status: Active
Phase: No phase specified
Type: Natural history/Epidemiology, Supportive care, Treatment
Age: 18 and over
Trial IDs: VICC URO 16133, NCI-2016-01795, NCT03016741
Start Over